Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

Details 詳細情報について

• CRID

  1362262943834608512

• DOI

  10.1016/s1470-2045(17)30566-1

• ISSN

  14702045

• Web Site

  https://api.elsevier.com/content/article/PII:S1470204517305661?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S1470204517305661?httpAccept=text/plain

• Data Source

  • Crossref